European Patent Office Notifies Intention To Grant for Evolution Biotechnology Patent EP3331366 “Acaricides” - Evolution Biotechnologies
post-template-default,single,single-post,postid-9134,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

European Patent Office Notifies Intention To Grant for Evolution Biotechnology Patent EP3331366 “Acaricides”

Bedford, UK, January 9th, 2019

Evolution (, the UK and US-based company pioneering the use of biological control to benefit human health, today reports the announcement by the European Patent Office of notification of intention to grant Evolution’s patent EP3331366, “Acaricides”.

The patent protects Evolution’s lead technology, developing a biological control for the house dust mite as a preventative for asthma.

The patent provides broad protection for any use of replicating biological agents for the control of house dust mites (HDM). The first claim protects “A method of treating or preventing a house dust mite infestation, said method comprising applying an acaricidal infectious agent at a site of a house dust mite infestation, or at a site proximal thereto, or at a site at risk of such infestation.”

As a result of this decision, Evolution now has exclusive control of the European market for this uniquely capable technology, with the potential to treat multiple mite habitats from a limited initial application. This market is projected to have potential for sales of more than $680M per annum in western Europe alone.

Grant in Europe is anticipated in the first half of 2019, with grant in Hong Kong following a quarter later. Corresponding applications are queued for examination in the USA, Australia, and Japan and will leverage our highly favourable PCT international examination report (IPRP).
Dr. David Harper, Evolution’s CEO, said “this is a huge step forward for the company, providing exclusivity for this uniquely capable approach in one of the largest markets in the world, with additional filings progressing in other areas.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027 and US company 6050853) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial target is the development of a novel, self-amplifying biological control for the house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”. Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:



No Comments

Sorry, the comment form is closed at this time.